Global Markets Direct's, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015', provides an overview of the Herpes Labialis (Oral Herpes)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Browse Detail Report With TOC @ http://www.radiantinsights.com/research/herpes-labialis-oral-herpes-pipeline-review-h2-2015
Scope
The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
No comments